SEC Form 4 · accession 0000899243-17-015163
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R. Kasinger
Officer — General Counsel and Secretary
Period of report
May 31, 2017
Accepted (ET)
Jun 2, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $13.62 | May 31, 2017 | A | 123,000 | A | — | May 31, 2027 | Common Shares | 123,000 | 123,000 | D |
Explanation of responses
- F1This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.